Yes, Suboxone is an opioid.
Suboxone (buprenorphine/naloxone) is classified as a Schedule III opioid analgesic 1. The buprenorphine component is a partial agonist at the mu-opioid receptor, which makes it pharmacologically an opioid, albeit with unique properties that distinguish it from full opioid agonists 2.
Pharmacological Classification
Buprenorphine functions as:
- Partial agonist with very high binding affinity for the mu-opioid receptor
- Antagonist with high binding affinity for delta- and kappa-opioid receptors
- Agonist with low binding affinity for the opioid receptor-like 1 receptor 1
This partial agonist activity means buprenorphine produces typical opioid effects (analgesia, euphoria, respiratory depression) but with a ceiling effect, particularly for respiratory depression 2. The FDA drug label confirms that chronic administration produces dependence of the opioid type, characterized by moderate withdrawal upon abrupt discontinuation 3.
Regulatory Status
The FDA explicitly classifies Suboxone as a controlled Schedule III narcotic under the Controlled Substances Act 3. This regulatory designation reflects its opioid properties and potential for dependence, though it is considered to have lower abuse potential than Schedule II full opioid agonists.
Clinical Context
The naloxone component in Suboxone does not change buprenorphine's opioid classification. When taken sublingually as prescribed, naloxone is poorly absorbed and exerts no clinically significant effect 4. The naloxone is present solely as a deterrent to intravenous misuse—if the combination is injected, naloxone precipitates withdrawal in opioid-dependent individuals 3.
Important clinical distinction: While buprenorphine is an opioid, its partial agonist properties give it advantages over full agonists, including a ceiling effect for respiratory depression, lower abuse potential, and milder withdrawal symptoms 1. These properties make it uniquely suited for treating opioid use disorder while maintaining its classification as an opioid medication.
The 2025 NCCN guidelines explicitly state that buprenorphine may be considered as a "first-line opioid" for cancer pain management in patients with opioid use disorder 1, further confirming its status as an opioid medication with therapeutic applications in both pain management and addiction treatment.